LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

Search

TransMedics Group Inc

Chiusa

SettoreSettore sanitario

73.67 -2.19

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.59

Massimo

75.5

Metriche Chiave

By Trading Economics

Entrata

-98M

7.3M

Vendite

13M

174M

P/E

Media del settore

17.279

49.712

EPS

0.3

Margine di Profitto

4.206

Dipendenti

898

EBITDA

-4.9M

28M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+59.25% upside

Dividendi

By Acuity

Utili prossimi

29 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-744M

2.6B

Apertura precedente

75.86

Chiusura precedente

73.67

Notizie sul Sentiment di mercato

By Acuity

50%

50%

128 / 342 Classifica in Healthcare

TransMedics Group Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Chi Siamo TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat